CollPlant Biotechnologies Ltd. (CLGN) vs PharmaCyte Biotech, Inc. (PMCB)
A side-by-side comparison of CollPlant Biotechnologies Ltd. and PharmaCyte Biotech, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CLGN
CollPlant Biotechnologies Ltd.
$3.34HealthcareDelayed quote: Oct 6, 2026, 3:04 PM EDT
PMCB
PharmaCyte Biotech, Inc.
$0.42HealthcareDelayed quote: Oct 6, 2026, 3:00 PM EDT
Total return — CLGN vs PMCB
growth of $100 · dividends reinvested · last 9yCLGN -96.2% (-30.5%/yr)PMCB -99.7% (-46.7%/yr)CLGN compounded faster over this window
Log scale — wide-divergence pair
CLGN PMCB
CLGN vs PMCB: by the numbers
- •PMCB is the larger company ($4M vs $4M market cap).
- •Both run net losses; PMCB's is the smaller (0.00% vs -3934.91% net margin).
Metrics side by side
Valuation
| Metric | CLGN | PMCB |
|---|---|---|
| P/S ratio | 13.60 | N/A |
| P/B ratio | 1.47 | 0.16 |
Profitability
| Metric | CLGN | PMCB |
|---|---|---|
| Gross margin | 26.32% | 0.00% |
| Operating margin | -484.31% | 0.00% |
| Net margin | -3934.91% | 0.00% |
| ROE | -424.89% | -54.15% |
| ROIC | -221.32% | -19.51% |
Growth (annualized)
| Metric | CLGN | PMCB |
|---|---|---|
| Revenue CAGR (5Y) | -56.28% | N/A |
| Total return CAGR (5Y) | -53.69% | -33.59% |
Frequently asked
- How have CLGN and PMCB total returns compared?
- Over the past 5 years, CLGN delivered -53.69% and PMCB delivered -33.59% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.